Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease

J Clin Gastroenterol. 2010 Jul;44(6):e116-22. doi: 10.1097/MCG.0b013e3181c8a50f.

Abstract

Background: The aims of this study were to evaluate the efficacy of medical treatments and to identify factors to predict clinical outcome of intestinal Behçet disease (BD) during medical treatment.

Methods: We performed a retrospective review of the medical records of 93 patients who were diagnosed and medically treated with intestinal BD at Severance Hospital, Seoul, Korea from 1992 to 2007. A therapeutic response was evaluated 8 weeks after the initiation of medical treatment, and cumulative recurrence and surgery rates were also assessed during long-term follow-up.

Results: The initial remission rate at 8 weeks after treatment was 66.7%. During the follow-up period, cumulative recurrence rates for intestinal BD were 24.9% at 2 years and 43.0% at 5 years. The recurrence rate was significantly higher in patients with apparent gastrointestinal symptoms at their initial presentation, volcano-type and deep intestinal ulcers, and those who failed to achieve complete remission during the initial treatment. Cumulative rates for surgery were 6.7% at 2 years and 15.1% at 5 years. The typical type of ulcers was the only predictive factor for the likelihood of surgery.

Conclusions: Our study demonstrates that a considerable number of patients experience disease relapse during follow-up despite a high-remission rate after medical treatment for intestinal BD. Careful observation and intensive treatment should be carried out, especially in patients without complete remission after initial treatment, with deep and volcano-shaped ulcers, or with apparent gastrointestinal symptoms at the time of diagnosis.

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / administration & dosage
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Azathioprine / administration & dosage
  • Behcet Syndrome* / drug therapy
  • Behcet Syndrome* / pathology
  • Behcet Syndrome* / prevention & control
  • Behcet Syndrome* / surgery
  • Colchicine / administration & dosage
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Intestinal Diseases* / drug therapy
  • Intestinal Diseases* / pathology
  • Intestinal Diseases* / surgery
  • Korea
  • Male
  • Mesalamine / administration & dosage
  • Middle Aged
  • Prognosis
  • Recurrence
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Ulcer* / drug therapy
  • Ulcer* / pathology
  • Ulcer* / surgery
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • Mesalamine
  • Azathioprine
  • Colchicine